Potential Drug Delivery Research Articles

Lipid-Based Nanoparticles as Drug Delivery System for Modern Therapeutics.

The emergence of lipid-based nanoparticulate systems has significantly reshaped the landscape of drug delivery. This review aims to encapsulate the advancements, challenges, and potential of lipid-based nanoparticulate drug delivery in modern therapeutics. Lipid-based nanoparticles, including liposomes, lipid nanoparticles, and solid lipid nanoparticles, harness the biocompatibility and biodegradability of lipids to encapsulate and deliver a diverse range of therapeutic agents. This platform offers solutions to various drug delivery challenges, such as enhancing drug solubility and bio- availability, achieving controlled and sustained release, targeted delivery, and co-delivery of multi-agents. These nanoparticles have demonstrated potential in overcoming biological barriers, including the blood-brain barrier, mucosal barriers, and cellular barriers, enabling the delivery of drugs to previously inaccessible sites. Biocompatibility and reduced toxicity are intrinsic attributes of lipid-based nanoparticles, minimizing immune responses and systemic toxicity while promoting personalized medicine possibilities. However, challenges in formulation, stability, and regulatory approval underscore the need for ongoing research and innovation in this field.

Biopharmaceutical modulatory effects of newly engineered bile acid-Tyloxapol nanogels for attenuation of cytotoxicity in auditory cells

This study presents novel thermoresponsive nanogels composed of chenodeoxycholic acid and Tyloxapol for potential inner ear drug delivery. The nanogels exhibit non-Newtonian, shear-thinning fluid behaviour and rapid gelation at body temperature. Biocompatibility studies were conducted on auditory and macrophage cell lines. Nanogels had a minimal impact on cellular viability, glycolysis, and mitochondrial respiration of auditory cells after 24 h of exposure. However, mitochondrial function analysis in macrophages revealed a significant decrease in oxidative phosphorylation and coupling efficiency after nanogel exposure, accompanied by increased proton leakage. Despite these metabolic disruptions, glycolysis remained unaffected. The Poloxamer matrix appears to be responsible for these effects, independent of the presence of bile acids or Tyloxapol. This study highlights the potential of bile acid-enriched nanogels in drug delivery, particularly their biocompatibility and injectability while acknowledging challenges related to mitochondrial dysfunction in immune cells. These findings suggest that thermoresponsive bile acid and Tyloxapol nanogels have the potential to be safe and effective drug delivery vehicles for inner ear applications.

Advances in colon-targeted drug technologies

Purpose of review Herein, we present an overview of innovative oral technologies utilized in colonic drug delivery systems that have made significant translational and clinical advancements to treat inflammatory bowel disease (IBD) in recent years. Recent findings The colon is home to distinct physiological conditions, such as pH and microbiota, that have been exploited in the development of colonic drug delivery systems for the treatment of local and systemic diseases. However, given the intra and interindividual variability in the gastrointestinal tract of both healthy and diseased states, various systems have shown inconsistencies in targeted drug release to the colon. Recent breakthroughs have led to systems that incorporate multiple independent trigger mechanisms, ensuring drug release even if one mechanism fails due to physiological variability. Such advanced platforms have bolstered the development of oral biologics delivery, an especially promising direction given the lack of commercially available oral antibody medications for IBD. These concepts can be further enhanced by employing 3D printing which enables the personalisation of medicines. Summary Leveraging these novel technologies can accurately deliver therapeutics to the colon, allowing for treatments beyond gastrointestinal tract diseases. To realize the full potential of colonic drug delivery, it is paramount that research focuses on the clinical translatability and scalability of novel concepts.

Incrimination and impact on recovery times and effects of BN nanostructures on antineoplastic drug-electronic density study.

By delivering the drug to the intended cell location, the use of nanomaterials in the drug delivery system may influence how the patient receives the medication and may assist in mitigating severe side effects. Density functional theory was used to assess the use of boron carbon nitride nanocages (BNCNCs), boron nitride (BNNSs), and boron carbon nitride nanosheets (BNCNSs) as melphalan (Mln) drug carriers in both the gaseous and fluid phases. We systematically examined the dipole moment, density of states, frontier molecular orbital, and optimal adsorption energy to understand the targeted drug delivery potential of these nanostructures. Adsorption energy analysis revealed that in both gas and water media, Mln drug adsorption takes place spontaneously on all the conjugated structures. The occurrence of adsorption energy as physisorbed energy suggests that the process is reversible, and desorption can take place with a much lower energy input. This physical contact is appropriate for the unquestionable unloading of Mln medications to the intended location. The reactivity is higher in BNNSs and BNCNSs, while the stability is higher in BNCNCs. The recovery time shows a shorter time for BNNSs and BNCNSs, while BNCNC shows a potential desorption time in higher temperature. These conclusions are corroborated by the results of the quantum theory of atoms in molecules (QTAIM). After the interaction analysis, it was observed that the BNCNCs can act as potential carriers for the melphalan. From dipole moment analysis, all three nanostructures show a high hydrophilic nature but quite higher in BNCNCs after doping in both media. Overall, all the structures show the potential carrier for melphalan drug. The quantum mechanical approach, or DFT, has been used to study the fundamental structural, electrical, thermodynamic, and other aspects of proposed structures to develop an acceptable Mln drug detector. The adsorbate and all adsorbents were optimized via the hybrid B3LYP functional and the 6-311G + + (2d, p) basis set approach prior to the adsorption process. The Gaussian 09 package was used at 298K as the constant temperature and 1 atm as the constant pressure. The structures are examined using the same functional models for solvation analysis-6-311 G + + (2d, p) and B3LYP-as well as the polarized continuum model (PCM) model as the foundation set. Density of states was studied using GaussSum 3.0 software. The interaction studies QTAIM and RDG were studied using VMD and Multiwfn software.

Effect of Hydroxyapatite Nanoparticle Crystallinity and Colloidal Stability on Cytotoxicity.

Hydroxyapatite nanoparticles (nHA) have gained attention as potential intracellular drug delivery vehicles due to their high binding affinity for various biomolecules and pH-dependent solubility. Yet, the dependence of nHA cytocompatibility on their physicochemical properties remains unclear since numerous studies have revealed starkly contrasting results. These discrepancies may be attributed to differences in size, shape, crystallinity, and aggregation state of nHA, which complicates fundamental understanding of the factors driving nHA cytotoxicity. Here, we hypothesize that nHA cytotoxicity is primarily driven by intracellular calcium levels following the internalization of nHA nanoparticles. By investigating the cytotoxicity of spherical nHA with different crystallinity and dispersity, we find that both lower crystallinity and increased agglomeration of nHA raise cytotoxicity, with nanoparticle agglomeration being the more dominant factor. We show that the internalization of nHA enhances intracellular calcium levels and increases the production of reactive oxygen species (ROS). However, only subtle changes in intracellular calcium are observed, and their physiological relevance remains to be confirmed. In conclusion, we show that nHA agglomeration enhances ROS production and the associated cytotoxicity. These findings provide important guidelines for the future design of nHA-containing formulations for biomedical applications, implying that nHA crystallinity and especially agglomeration should be carefully controlled to optimize biocompatibility and therapeutic efficacy.

A first-principles adsorption study of functionalized carbon, boron nitride, silicon carbon nanotubes with ifosfamide as vehicles for drug delivery: Thermal analysis

We investigated the adsorption of ifosfamide (IFS) on the outer surface of zigzag (10, 0) carbon nanotubes (CNT), boron nitride nanotubes (BNNT), and silicon carbon nanotubes (SiCNT), using density functional theory (DFT) calculations at the PBE-D3 level in a water solvent phase. Based on zero-point corrected binding energies (Ebin), IFS exhibits chemisorption through its O-head and Cl-head on CNT (−1.05 eV) compared to BNNT (−0.93 eV), characterized by covalent interaction. In contrast, IFS undergoes physisorption via its O-head on SiCNT with binding energy of −0.68 eV as the most stable model this interaction is driven by electrostatic forces. The formation of complexes between the drug and nanotubes is influenced by charge transfer dynamics. Our thermodynamic analysis demonstrates the Gibbs free energy (ΔG) and enthalpy energy (ΔH) for all models are exothermic and spontaneous. The observed decrease in binding energy for BNNT and CNT correlates with changes in their energy gap, dipole moment, and charge transfer upon IFS adsorption. Notably, SiCNT exhibits a different response with a significant energy gap change leading to an increase in dipole moment and charge transfer. These findings suggest that these nanotubes demonstrate promising sensitivity to the presence of IFS and could be explored as potential drug delivery systems for this drug.

Novel sodium tauroursodeoxycholate-based multifunctional liposomal delivery system for encapsulation of oleanolic acid and combination therapy of type 2 diabetes mellitus

Liposomes have demonstrated great potential for drug delivery and diabetes treatment. However, hydrolysis by enzymes and emulsification by endogenous bile salts make liposomes unstable in the gastrointestinal tract. In this study, sodium tauroursodeoxycholate (TUDCNa)-based multifunctional bilosomes were designed to address the deficiencies of conventional liposomes. In the designed bilosomes, cholesterol was replaced by TUDCNa, which served as both a membrane stabilizer and an antidiabetic drug. Oleanolic acid (OA) was encapsulated in both conventional liposomes (OA-Ch-Lip) and bilosomes (OA-Tu-Bil) to compare their properties. Firstly, OA-Tu-Bil exhibited similar encapsulation efficiency and drug loading compared to OA-Ch-Lip, but with a smaller particle size. Secondly, OA-Tu-Bil showed better stability than OA-Ch-Lip. Thirdly, bilosomes exhibited prolonged intestinal retention time and improved permeability and oral bioavailability. Fourthly, in type 2 diabetes mellitus (T2DM) mice model, TUDCNa synergized with OA to exhibit the strongest therapeutic effect. In conclusion, TUDCNa have demonstrated the ability to substitute cholesterol in conventional liposomes, it provided a new approach for oral delivery of hypoglycemic drugs, and offered an innovative strategy for combination therapy.

Freeze-thawed electrosprayed everolimus loaded nanoparticles as a potential drug delivery system in brain tumours: Design and characterisation

Freeze-thawing is a method that has proven beneficial to achieve cross-linking without the use of chemicals. In this study, the aim was to evaluate the applicability of our previously electrosprayed polyvinyl alcohol (PVA)- soluplus (SOL®)-everolimus (RAD001) nanoparticles (NP) as a potential drug delivery system in brain tumours post freeze-thawing. The effects of several formulation variables post freeze-thawing (particle size, encapsulation efficiency (EE%) and % drug release) were investigated using the Box-Behnken (BBD) design of experiment. The optimal PVA-SOL®-RAD001 NP formulation contained 2%PVA-14%SOL®-0.6 % RAD001 with a gelation temperature of 37 °C ± 0.1 at pH 5.5. The average particle size, EE%, and release kinetics of the PVA-SOL®-RAD001 NP were (63.99 ± 0.1) nm, 99 %, and 93 % in 8 h respectively. For the in vitro cell viability tests, the NP were treated at 24h and 48h showing a significant reduction in cell viability at the higher dose treatments for the optimized formulation. Additionally, a comparison was made with our previously developed microspheres containing PVA-RAD001 alone, for the cell viability study. Electrosprayed protocol modifications were proposed to produce NP combining smaller particle size (<100 nm) with higher encapsulation efficiency and to ensure the optimum viscosity at body temperature highlighting the novelty of the freeze-thaw technique on the electrosprayed NP.

Enzymatically Triggered Drug Release from Microgels Controlled by Glucose Concentration.

This study aims to design microgels for controlled drug release via enzymatically generated pH changes in the presence of glucose. Modern medicine is focused on developing smart delivery systems with controlled release capabilities. In response to this demand, we present the synthesis, characterization, and enzymatically triggered drug release behavior of microgels based on poly(acrylic acid) modified with glucose oxidase (GOx) (p(AA-BIS)-GOx). TEM images revealed that the sizes of air-dried p(AA-BIS)-GOx microgels were approximately 130 nm. DLS measurements showed glucose-triggered microgel size changes upon glucose addition, which depended on buffer concentration. Enzymatically triggered drug release experiments using doxorubicin-loaded microgels with immobilized GOx demonstrated that drug release is strongly dependent on glucose and buffer concentration. The highest differences in release triggered by 5 and 25 mM glucose were observed in HEPES buffer at concentrations of 3 and 9 mM. Under these conditions, 80 and 52% of DOX were released with 25 mM glucose, while 47 and 28% of DOX were released with 5 mM glucose. The interstitial glucose concentration in a tumor ranges from ∼15 to 50 mM. Normal fasting blood glucose levels are about 5.5 mM, and postprandial (2 h after a meal) glucose levels should be less than 7.8 mM. The obtained results highlight the microgel's potential for drug delivery using the enhanced permeability and retention (EPR) effect, where drug release is controlled by enzymatically generated pH changes in response to elevated glucose concentrations.

Recent Advances in Ocular Drug Delivery: Insights into Lyotropic Liquid Crystals.

Background/Objectives: This review examines the evolution of lyotropic liquid crystals (LLCs) in ocular drug delivery, focusing on their ability to address the challenges associated with traditional ophthalmic formulations. This study aims to underscore the enhanced bioavailability, prolonged retention, and controlled release properties of LLCs that significantly improve therapeutic outcomes. Methods: This review synthesizes data from various studies on both bulk-forming LLCs and liquid crystal nanoparticles (LCNPs). It also considers advanced analytical techniques, including the use of machine learning and AI-driven predictive modeling, to forecast the phase behavior and molecular structuring of LLC systems. Emerging technologies in biosensing and real-time diagnostics are discussed to illustrate the broader applicability of LLCs in ocular health. Results: LLCs are identified as pivotal in promoting targeted drug delivery across different regions of the eye, with specific emphasis on the tailored optimization of LCNPs. This review highlights principal categories of LLCs used in ocular applications, each facilitating unique interactions with physiological systems to enhance drug efficacy and safety. Additionally, novel applications in biosensing demonstrate LLCs' capacity to improve diagnostic processes. Conclusions: Lyotropic liquid crystals offer transformative potential in ocular drug delivery by overcoming significant limitations of conventional delivery methods. The integration of predictive technologies and biosensing applications further enriches the utility of LLCs, indicating a promising future for their use in clinical settings. This review points to continued advancements and encourages further research in LLC technology to maximize its therapeutic benefits.

Targeted delivery of letrozole-loaded Mg-doped cobalt ferrite nanoparticles for breast cancer treatment

Breast cancer is the most common cancer in women globally. Letrozole is an aromatase inhibitor used as an anticancer drug. Conventional Letrozole therapies for breast cancer often cause adverse effects when administered orally or parenterally. Efforts have been made to develop an advanced drug delivery system for breast cancer treatment, aiming to improve drug release accuracy and therapeutic efficacy while minimizing side effects. This study focuses on magnesium-doped cobalt ferrite nanoparticles (Mg-doped CFNPs) as potential drug delivery carrier for breast cancer treatment. Mg-doped CFNPs with the chemical formula Co1-xMgxFe2O4 (where x = 0.0, 0.05, 0.10, 0.15, 0.20 and 0.25) were synthesized with different concentrations of 5 %, 10 %, 15 %, 20 %, and 25 % by the sol gel method with a fine size of 30–70 nm and their characteristics such as surface morphology, structural properties, chemical composition, and charge were investigated using scanning electron microscopy (SEM), X-ray diffraction (XRD), Fourier transform infrared spectroscopy (FTIR), and zeta potential analysis respectively. After synthesis, the Mg-doped CFNPs were coated with Poly ethylene glycol (PEG) and encapsulated with Letrozole, which exhibited <10 % hemolytic activity across all concentrations, as well as minimal cytotoxic effects on non-cancerous cells (HEK-293) but exhibited significant toxicity towards breast cancer cell lines (MCF-7, MDA-MB-231).The best results were obtained at a concentration of 25 % in both the hemolytic assay and the MTT assay, which indicated that increasing the amount of magnesium in cobalt decreased the toxicity and increased the drug release efficiency of nanoparticles.

Thermosensitive Hydrogels as Targeted and Controlled Drug Delivery Systems: Potential Applications in Transplantation.

Drug delivery in transplantation plays a vital role in promoting graft survival, preventing rejection, managing complications, and contributing to positive patient outcomes. Targeted and controlled drug delivery can minimize systemic effects. Thermosensitive hydrogels, due to their unique sol-gel transition properties triggered by thermo-stimuli, have attracted significant research interest as a potential drug delivery system in transplantation. This review describes the current status, characteristics, and recent applications of thermosensitive hydrogels for drug delivery. Studies aimed at improving allotransplantation outcomes using thermosensitive hydrogels are then elaborated on. Finally, the challenges and opportunities associated with their use are discussed. Understanding the progress of research will serve as a guide for future improvements in their application as a means of targeted and controlled drug delivery in translational therapeutic applications for transplantation.

Modified Release Interpenetrating Polymeric Network Hydrogel Beads of Montelukast Sodium Via Box Behnken Design

Background: Interpenetrating Polymeric Networks (IPN) are cross-linked polymeric alloys developed when two or more cross-linked polymers inter-penetratingly entangle. Interpenetrating polymeric networks possess several benefits including stability, biocompatibility, biodegradability, high swelling ability, and modified release efficiency. Aim: The aim of this study is to design stable, control-released montelukast sodium-loaded IPN hydrogel beads as a promising approach toward drug delivery. Objective: The goal of the present work was to develop Chitosan (swellable polymer) and glutaraldehyde (cross-linker) based modified (controlled) released montelukast sodium IPN hydrogel beads. Methods: The montelukast sodium IPN hydrogel beads were prepared via the precipitation method, and the final batch of IPN hydrogel beads was based on particle size, percent entrapment efficiency, area of swelling, and cumulative percent drug release using an overlay plot in Box-Behnken design. Compatibility studies (DSC, FT-IR) and microscopical observation (SEM) confirmed the compatibility and sphericity of the formulations. Results: The optimized (comprising 2.01% chitosan and 0.48% glutaraldehyde) IPN hydrogel beads having satisfactory particle size (817.76±54.49 μm), good entrapment efficiency (71.36±3.04%), and area of swelling (27.00±1.68 mm2) showed swelling and pH-dependent controlled montelukast release (92.96±1.05%) after 12 h with longer duration of action. Conclusion: The prepared montelukast sodium IPN hydrogel beads could be a potent control-released drug delivery vehicle.

5-Fluorouracil adsorption on graphene oxide-amine modified graphene oxide/hydroxyapatite composite for drug delivery applications: Optimization and release kinetics studies

The present study focused on investigation of graphene oxide/hydroxyapatite (GO/HAp) and amine modified graphene oxide/hydroxyapatite (GO-NH2/HAp) composites as potential drug carrier agents for 5-Fluorouracil (5-FU). Incorporation of 5-Fluorouracil drug was performed via adsorption through π-π interactions and electrostatic attractions. Modification of graphene oxide was performed for the production of amine modified graphene oxide/hydroxyapatite composite with the intention of enhancing adsorption performance. The X-Ray Diffraction (XRD), Fourier Transform Infrared Spectroscopy (FTIR), Thermogravimetric Analysis (TGA) and zeta potential/particle size analysis were performed for particle characterization while Scanning Electron Microscopy (SEM) and Transmission Electron Microscopy (TEM) analysis were used to analyze detailed morphological properties. Experimental design studies were followed out in order to determine the effect of adsorption parameters including graphene oxide amount, pH and initial drug concentration on 5-Fluorouracil adsorption behavior. Adsorption isotherms of both composites with unmodified and modified GO were best fitted to Freundlich model with R2 values of 0.9616 and 0.9682 respectively. The maximum adsorption capacities (qm) were calculated as 47.3 mg/g and 18.4 for graphene oxide/hydroxyapatite and amine modified graphene oxide/hydroxyapatite composites respectively at pH 2.0. The highest adsorption percentage was obtained for amine modified graphene oxide/hydroxyapatite composite as 40.87 % at pH 2.0 condition. In vitro release kinetic studies revealed that compliance with Higuchi and Korsmeyer-Peppas kinetic models were observed for graphene oxide/hydroxyapatite, whereas zero order and Korsmeyer-Peppas kinetic models pointed out as the well-fitted model for amine modified graphene oxide/hydroxyapatite composite. The release period of 5-FU drug from all composites were continued up to 8–10 h in physiological conditions (pH 7.4, 37 °C) indicating an achieved controlled release. Based on the overall findings, graphene oxide/hydroxyapatite and amine modified graphene oxide/hydroxyapatite composites could be suggested as a potential drug delivery agent for 5-FU in clinical applications.

TRPV1-targeted ion-responsive hydrogel against pyroptosis of dry eye disease

Dry eye disease (DED) is a complex ocular surface abnormality characterized by tear film hyperosmolarity, inflammation, and damage. Left untreated, DED can lead to a self-perpetuating vicious cycle of worsening symptoms. Existing treatments for DED face challenges related to limited drug delivery to the ocular surface and potential side effects from nonspecific drug targeting. In an effort to address these issues, we developed a novel ion-responsive in situ gelling system targeting the transient receptor potential vanilloid 1 (TRPV1), based on co-assembly of the hydrogelator KFQ12 with the functional peptide V1-Cal. The KFQ12/V1-Cal (KVC) aqueous solution, when dripped and mixed with the ionic tear film on the ocular surface, rapidly transformed into a honeycomb-like hydrogel. This hydrogel exhibited prolonged retention on the ocular surface, serving as a stable scaffold for corneal epithelium regeneration and providing protection against external pathogens while maintaining gas exchange. In a murine model of DED, the KVC hydrogel demonstrated superior therapeutic efficacy due to its sustained release characteristics and specific inhibition of the TRPV1 channel activated by hyperosmotic or desiccating stress. By performing transcriptome sequencing and experimental validation both in vivo and in vitro, we confirmed the mechanism of the TRPV1-Ca2+-Pyroptosis axis in the pathogenesis of DED. Our research provides novel perspectives on the understanding and treatment of DED, and introduces a potential ocular surface drug delivery system characterized by superior biosafety, prolonged retention, and improved therapeutic outcomes.

Ethosuximide-loaded bismuth ferrite nanoparticles as a potential drug delivery system for the treatment of epilepsy disease.

Encapsulating antiepileptic drugs (AEDs), including ethosuximide (Etho), into nanoparticles shows promise in treating epilepsy. Nanomedicine may be the most significant contributor to addressing this issue. It presents several advantages compared to traditional drug delivery methods and is currently a prominent area of focus in cancer research. Incorporating Etho into bismuth ferrite (BFO) nanoparticles within diverse controlled drug delivery systems is explored to enhance drug efficacy. This approach is primarily desired to aid in targeted drug delivery to the brain's deepest regions while limiting transplacental permeability, reducing fetal exposure, and mitigating associated adverse effects. In this investigation, we explored Etho, an antiepileptic drug commonly employed for treating absence seizures, as the active ingredient in BFO nanoparticles at varying concentrations (10 and 15 mg). Characterization of the drug-containing BFO nanoparticles involved scanning electron microscopy (SEM) and elemental analysis. The thermal properties of the drug-containing BFO nanoparticles were evaluated via differential scanning calorimetry (DSC) analysis. Cytotoxicity evaluations using the MTT assay were conducted on all nanoparticles, and human neuroblastoma cell line cultures (SH-SY5Y) were treated with each particle over multiple time intervals. Cell viability remained at 135% after 7 days when exposed to 15 mg of Etho in BFO nanoparticles. Additionally, in vitro drug release kinetics for Etho revealed sustained release lasting up to 5 hours with a drug concentration of 15 mg.

Dexamethasone acetate loaded poly(ε-caprolactone) nanofibers for rat corneal chemical burn treatment

Topical eye drop approaches to treat ocular inflammation in dry eyes often face limitations such as low efficiency and short duration of drug delivery. Nanofibers serve to overcome the limitation of the short duration of action of topical eye drops used against ocular inflammation in dry eyes. Several attempts to develop suitable nanofibers have been made; however, there is no ideal solution. Here, we developed polycaprolactone (PCL) nanofibers loaded with dexamethasone acetate (DEX), prepared by electrospinning, as a potential ocular drug delivery platform for corneal injury treatment. Thirty-nine Sprague Dawley rats (7 weeks old males) were divided into four treatment groups after alkaline burns of the cornea; negative control (no treatment group); dexamethasone eyedrops (DEX group); PCL fiber (PCL group); dexamethasone loaded PCL (PCL + DEX group). We evaluated therapeutic efficacy of PCL + DEX by examining the epithelial wound healing effect, the extent of corneal opacity and neovascularization. Additionally, various inflammatory factors, including IL-1β, were investigated through immunochemistry, western blot analysis, and quantitative real-time RT-PCR (qRT-PCR). PCL + DEX group showed histologically alleviated signs of corneal inflammation compared with DEX group, which showed a decrease in IL-1β and MMP9 in the corneal stroma. The quantitative expression on day 1 after alkaline burn of pro-inflammatory markers, including IL-1β and IL-6, in the PCL + DEX group was significantly lower than that in the DEX group. Notably, PCL + DEX treatment significantly suppressed neovascularization, and enhanced the anti-inflammatory function of DEX during the acute phase of ocular inflammation. Collectively, these findings suggest that PCL + DEX may be a promising approach to effective drug delivery in corneal burn injuries.

Exploration of Metal-Doped Iron Oxide Nanoparticles as an Antimicrobial Agent: A Comprehensive Review.

Over the past two decades, nanotechnology has captured significant interest, especially in the medical field, where the unique characteristics of nanoscale particles offer substantial advantages. The family of nanosized materials, specifically iron oxide nanoparticles (IONPs), has emerged as promising due to their magnetic properties, biocompatibility, and substantial surface area for therapeutic molecule attachment. The review explores various strategies to enhance the antibacterial properties of IONPs, such as metal doping, which modifies their physicochemical, biological, electrical, and optical properties. Metal-doped IONPs, including those with nickel, copper, zinc, selenium, molybdenum, gold, and others, have shown that they effectively eradicate viruses and bacteria. The mechanisms behind their enhanced antibacterial activity involve generating reactive oxygen species (ROS), inhibiting antibiotic-resistant genes, disrupting cell walls and DNA, dysfunction of efflux pumps, and internalizing nanoparticles. The review also addresses the potential toxicity of IONPs, highlighting factors such as their dimension, form, and outermost layers, which change how they affect the overall condition of cellular structures. Surface coatings using polymers and essential oils are among the strategies being investigated as potential ways to reduce toxicity. This review additionally looks into IONPs' drug delivery potential for antibiotics and antifungals. The integration of IONPs with various pharmaceutical compounds and their controlled release mechanisms are also detailed. The review concludes by offering a positive outlook on the potential enhancements and prospects of IONPs. Challenges in synthesis technologies, size tuning, and surface alteration are acknowledged, emphasizing the need for continued research to fully harness the capabilities of IONPs in biomedical applications.

Green composite synthesis based on aluminum fumarate metal-organic framework (MOF) for doxorubicin delivery: An in vitro study

The development of an eco-friendly and cost-effective drug delivery system (DDS) remains a challenge in cancer treatment. This study suggests a novel, eco-friendly, and cost-effective method to synthesize aluminum fumarate (A520) MOF using tangerine peel extract (TPE) as a pH-sensitive coating agent on a reduced graphene oxide (rGO) substrate. The system also incorporates the 2,2′-bipyridine dimethyltin diisothiocyanate complex, (Sn(bpy), as an organotin complex) to enhance therapeutic efficacy while minimizing off-target effects. In vitro cellular and molecular cytotoxicity examinations were conducted using HEK-293 and MCF-7 cell lines to evaluate cytotoxicity after 24 and 72 h. The findings of the MTT assay indicated that the final nanocarriers, without and with doxorubicin (DOX), exhibited relative cell viability of 95 % and 55 %, respectively, highlighting the system's potential for efficient and safe drug delivery. The TPE coating created a pH-sensitive DDS with high drug loading efficiency (DLE) (59.1 %) and low cytotoxicity. Drug release was studied over 200 h at pH 5.5 and 7.2. The augmented drug release profile (47 %) demonstrated a targeted release and successful inhibition of premature release in acidic environments due to pH-sensitive TPE molecules. The efficacy of targeted drug delivery to the MCF-7 cell was evaluated using 2D fluorescence microscopy, which demonstrated successful delivery of drugs to the cells. This innovative approach addresses the limitations of existing studies while promoting biocompatibility, stability, and functionality in DDSs.

Chloro-aluminum phthalocyanine encapsulation into liquid crystalline nanodispersions enhance skin penetration and phototoxicity in skin cancer cells

Non-melanoma skin cancer is one of the most common tumors in the world. Photodynamic therapy (PDT) is currently a non-invasive therapeutic option for the treatment of skin cancer and actinic keratosis. Chloro-aluminum phthalocyanine (AlClPc) is a second-generation photosensitizer that has been studied for application in PDT. However, it has the disadvantage of self-aggregating in a biological environment, which impairs its therapeutic action, making it a candidate for nanocarrier delivery. Among the nanocarriers, liquid crystalline nanodispersions (LCN) are biocompatible and present unique organizational characteristics that make them suitable for skin delivery of drugs. Herein, a new LCN based on oleic acid (OA), Phosal 75SA® containing or not D-α-Tocopherol polyethylene glycol 1000 succinate (TPGS) was developed and characterized aiming its application for skin cancer. The selected LCN with AlClPc showed nanometric size (152.3 ± 1.93 nm), adequate PDI (0.231 ± 0.009) and encapsulation efficiency (70.26 ± 3.87 %) and stability for 30 days. Also, LCN were characterized by polarized light microscopy and small angle X-ray diffraction (SAXS) resulting in hexagonal liquid crystalline nanodispersions. In the in vitro skin penetration test, LCN-AlClPc showed better penetration into the deeper skin layers than the control. LCN-AlClPc showed greater phototoxicity in the A431 tumor cell line than the control in the same cell line and also greater phototoxicity in A431 when compared to L929 fibroblast cells. Thus, LCN developed could improve the phototoxicity and skin penetration in vitro and are potential drug delivery systems for the treatment of non-melanoma skin cancer.